New York- Pfizer Inc. has announced promising topline data from its Phase 2b clinical trial (NCT04707313) evaluating the oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. The study achieved its primary endpoint, demonstrating a statistically significant change in body weight from baseline.
The twice-daily dosing of danuglipron exhibited notable reductions from baseline in body weight for all doses, ranging from -6.9% to -11.7%, compared to +1.4% for placebo at 32 weeks, and -4.8% to -9.4%, compared to +0.17% for placebo at 26 weeks. Placebo-adjusted reductions in mean body weight ranged from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks.
While observing common mild gastrointestinal adverse events, such as nausea (up to 73%), vomiting (up to 47%), and diarrhea (up to 25%), the study noted higher discontinuation rates, exceeding 50% across all doses compared to approximately 40% with placebo. No new safety signals were reported, and treatment with danuglipron did not exhibit an increased incidence of liver enzyme elevation compared to....READ MORE
Recently, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a...
Pfizer introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across th...
New York- Pfizer Inc. has announced promising topline data from its Phase 2b clinical trial (NCT04707313) evaluating the oral Glucagon-like peptide-1 receptor agonist (GL...
A virtual marketplace leading your business into the future
